Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research conducted by S.M. Campos and co-researchers has updated our knowledge about breast cancer
May 7th, 2009
"Patients developing visceral breast cancer metastases generally receive chemotherapy rather than endocrine therapy. Recent aromatase inhibitor studies have reported activity in such patients; therefore, this study formally evaluated anastrozole and exemestane in postmenopausal patients in this setting," scientists writing in the journal Clinical Breast Cancer report. "Postmenopausal women with advanced breast cancer and >= 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for >= 8 weeks. The primary endpoint was objective response In visceral lesions based on modified Response Evaluation...
Source: Women's Health Weekly (2009-05-07)
|
